Publication: Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis
Issued Date
2015-10-22
Resource Type
ISSN
1437160X
01728172
01728172
Other identifier(s)
2-s2.0-84941996279
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Rheumatology International. Vol.35, No.10 (2015), 1693-1699
Suggested Citation
Wanruchada Katchamart, Ajchara Koolvisoot, Emvalee Aromdee, Praveena Chiowchanwesawakit, Chayawee Muengchan Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatology International. Vol.35, No.10 (2015), 1693-1699. doi:10.1007/s00296-015-3271-8 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36058
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis
Other Contributor(s)
Abstract
© 2015, Springer-Verlag Berlin Heidelberg. The objective of this study was to investigate the association of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) status with disease progression and treatment outcomes in patients with rheumatoid arthritis (RA). A total of 276 adult patients who fulfilled the American College of Rheumatology 1987 classification criteria for RA were recruited from the Rheumatology clinic, Siriraj Hospital, from January 2011 to December 2012. Demographic, clinical, and laboratory data were collected at baseline and every 3 months up to 1 year of follow-up. RF and ACPA were measured at baseline. Radiography of the hands and feet was performed at baseline and 1 year. Patients with RF+/ACPA+ had significantly more severe disease activity and impaired functional status than those who had RF−/ACPA−. Although they received more aggressive treatment with methotrexate and combination of non-biologic, disease-modifying antirheumatic drug than other groups, fewer patients in this group achieved remission at 1 year of follow-up, especially when compared to RF−/ACPA− group (12 vs. 18 %). For radiographic erosion, patients with the presence of either RF or ACPA had a higher proportion of hand erosion than seronegative patients at baseline (77, 73, 83, and 32 %, p < 0.001 for RF+/ACPA+, RF+/ACPA−, RF−/ACPA+, and RF−/ACPA−, respectively). After 1 year of follow-up, patients who developed new erosion at the hands were more prevalent in RF+/ACPA+ (32 %) and RF+/ACPA− (33 %) groups. However, “newly developed” feet erosion was most common in RF+/ACPA− group (40 %) than in other groups. Patients with positive either RF or ACPA or both have more severe and aggressive disease that requires intensive treatment to improve outcomes.